Abbott India Limited (ABBOTINDIA) AI Stock Analysis

• Market Cap: ₹549.36B
• Dividend Yield: 1.68%
• Average Volume (3M): 628.00
• Price to Earnings (P/E): 41.0
• Beta (1Y): 0.62
• Revenue Growth: 10.69%
• EPS Growth: 17.46%
• Country: IN
• Employees: 3,814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 189.00
• Shares Outstanding: 21,249,302
• 10 Day Avg. Volume: 806
• 30 Day Avg. Volume: 628
• PEG Ratio: 2.57
• Price to Book (P/B): 15.22
• Price to Sales (P/S): 10.06
• P/FCF Ratio: 67.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹32,150.00
• Price Target Upside: 14.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 820.16
• Revenue Forecast (FY): ₹75.63B

• Rating: 67 Neutral
• Price Target: ₹27,992.00 ▼(-0.39% Downside)
• Action: Reiterated Date: 10/25/25
• Date: Action: Reiterated 10/25/25

Abbott India Limited's strong financial performance is the primary driver of its overall stock score, supported by robust profitability and a solid balance sheet. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.

Positive Factors

Balance sheet strength

Low leverage and a strong equity base provide durable financial flexibility: the company can fund salesforce investment, product support, or opportunistic M&A without relying on expensive external financing. This resilience supports operations through sector cycles and regulatory shocks over the next 2–6 months.

Negative Factors

Moderate revenue growth

Mid-single-digit top-line growth is modest for a branded-pharma player; without accelerated new product introductions or geographic diversification, revenue momentum may limit scale benefits and constrain faster margin expansion or meaningful market-share gains over the next several months.

Abbott India Limited Business Overview & Revenue Model

Company Description

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, pre-term labor, vita...

Read more

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, pre-term labor, vita...

How the Company Makes Money

Abbott India makes money primarily by selling branded pharmaceutical formulations and healthcare products in India. Its core revenue model is based on (1) domestic sales of prescription-led brands across multiple therapy areas, where demand is dri...

Read more

Abbott India makes money primarily by selling branded pharmaceutical formulations and healthcare products in India. Its core revenue model is based on (1) domestic sales of prescription-led brands across multiple therapy areas, where demand is dri...

Abbott India Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	67.12B	64.07B	58.47B	53.47B	49.10B	43.08B
Gross Profit	30.70B	28.96B	26.15B	23.63B	22.43B	19.10B
EBITDA	21.03B	19.70B	17.01B	13.60B	11.65B	10.01B
Net Income	15.09B	14.14B	12.01B	9.49B	7.99B	6.91B
Balance Sheet
Total Assets	56.94B	59.17B	51.93B	45.56B	42.24B	38.40B
Cash, Cash Equivalents and Short-Term Investments	23.42B	31.13B	21.18B	19.22B	27.35B	23.98B
Total Debt	1.82B	1.97B	832.30M	1.13B	1.52B	1.53B
Total Liabilities	16.84B	16.84B	14.95B	13.67B	14.04B	12.38B
Stockholders Equity	40.11B	42.33B	36.99B	31.89B	28.20B	26.02B
Cash Flow
Free Cash Flow	5.05B	9.59B	11.64B	8.59B	9.04B	7.03B
Operating Cash Flow	5.22B	10.12B	12.13B	8.93B	9.48B	7.27B
Investing Cash Flow	5.48B	1.82B	-4.16B	-1.48B	-3.96B	-718.20M
Financing Cash Flow	-10.40B	-9.25B	-7.45B	-6.39B	-6.37B	-5.82B

Abbott India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28101.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ABBOTINDIA, the sentiment is Negative. The current price of 28101.15 is above the 20-day moving average (MA) of 26424.68, above the 50-day MA of 26759.09, and below the 200-day MA of 29738.34, indicating a bearish trend. The MACD of -272.26 indicates Positive momentum. The RSI at 43.56 is Neutral, neither overbought nor oversold. The STOCH value of 26.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ABBOTINDIA.

Abbott India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	79 Outperform	₹775.43B	18.87	―	0.33%	7.33%	-3.79%
LUPIN	72 Outperform	₹1.05T	20.49	―	0.57%	15.49%	64.37%
ZYDUSLIFE	72 Outperform	₹897.11B	22.07	―	1.19%	14.01%	14.62%
ABBOTINDIA	67 Neutral	₹549.36B	41.01	―	1.68%	10.69%	17.46%
BIOCON	63 Neutral	₹566.77B	91.56	―	0.12%	10.62%	-66.88%
GLAXO	63 Neutral	₹398.91B	35.44	―	2.16%	4.17%	41.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%